Navigation Links
Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema

BASEL, Switzerland, April 25, 2007 - Basilea Pharmaceutica Ltd. (SWX:BSLN) reported today phase III study results showing that patients with severe chronic hand eczema can benefit from re-treatment with alitretinoin. In two previous randomized clinical trials, alitretinoin was found to be effective in treating severe chronic hand eczema in patients refractory to topical treatments. This pivotal trial demonstrated that patients responsive to initial treatment with alitretinoin can also benefit from additional treatment courses after eventual disease recurrence. The safety profile of alitretinoin observed in this study was consistent with that seen in previous trials. These positive data will be integrated into regulatory submissions planned for later this year.

Severe refractory Chronic Hand Eczema (CHE) is a relapsing disorder for which no approved treatment currently exists. This debilitating disease prevents patients from using their hands normally and requires frequent treatment interventions over time.

The objective of this re-treatment study was to describe the safety and efficacy of a second treatment course of alitretinoin in patients who achieved clear or almost clear hands after a previous initial treatment course. This study included 117 patients who eventually had disease recurrence, and 243 patients who had incomplete response after the initial treatment trial.

Patients who had disease recurrence were randomized in double blind manner to receive another 12 to 24 weeks treatment with either placebo or their previous dose of alitretinoin. Response rates were 80% for the alitretinoin 30mg group (Placebo 8.3%) and 48% for the 10mg group (Placebo 10%). These results indicate that alitretinoin is effective in treating severe refractory CHE in subsequent treatment courses.

Those patients who had either no or an incomplete response in the previous study received 30mg alitretinoin
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Efficacy and Safety Profile of Basileas Alitretinoin for Severe Refractory Chronic Hand Eczema Confirmed by Data Shown at European Dermatology Congress
2. Scientific Results Presented At ECCMID Demonstrate Well- Differentiated Profile of Basileas Two Phase III Anti- infective Compounds
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
(Date:6/17/2013)... 2013 The law firm of Rheingold, Valet, Rheingold, ... to be the first suit in New York ... user of two common anti-diabetic drugs, Byetta and Janumet (also ... resident Robert Cataletto , was filed on ... E.D.N.Y. CV 13-3411. Mr. Cataletto received prescriptions from ...
(Date:6/17/2013)... June 17, 2013   Southern Research Institute ... has been selected by its Board of Directors to ... July 8, 2013.   (Photo: http://photos.prnewswire.com/prnh/20130617/DC33167 ... Secrist, III, Ph.D., who served as president and CEO ... his retirement earlier this year after 34 years of ...
(Date:6/17/2013)... AVIV, Israel , June 17, 2013 ... the Board of Governors of the Israel-U.S. Binational Industrial ... million in funding for fourteen new projects between Israeli ... BIRD , the projects will access private sector ... approximately $33 million. The semi-annual meeting was held at ...
Breaking Medicine Technology:Suit filed for Pancreatic Cancer By Use of Byetta, Januvia and Janumet 2Southern Research Institute Names Arthur J. Tipton, Ph.D. President and CEO 2Southern Research Institute Names Arthur J. Tipton, Ph.D. President and CEO 3BIRD - Israel - U.S. Binational Industrial R&D Foundation to Invest $11 Million in 14 new Projects 2BIRD - Israel - U.S. Binational Industrial R&D Foundation to Invest $11 Million in 14 new Projects 3BIRD - Israel - U.S. Binational Industrial R&D Foundation to Invest $11 Million in 14 new Projects 4
... 2011 Time is money, and time that is wasted looking ... A first-of-its-kind mobile and HTML5 app released by Providian Medical ... both time and money. With just a few quick and easy ... the optimum ultrasound machines based on their individual needs. The app ...
... SuccessEHS will sponsor the California Primary Care Association (CPCA) ... statewide leader and recognized voice representing the interests of ... CPCA represents more than 800 not-for-profit community clinics and ... SuccessEHS supports CPCA,s mission of eliminating ...
Cached Medicine Technology:Providian Medical Launches New Tool to Make Finding the Right Ultrasound Machine Easier Than Ever 2SuccessEHS Sponsors California Primary Care Association 2SuccessEHS Sponsors California Primary Care Association 3
(Date:6/17/2013)... social media push boosted the number of people who ... day, Johns Hopkins researchers found, suggesting social media might ... shortage in the United States. , The gains were ... created a way for users to share their organ ... make their status official on state department of motor ...
(Date:6/17/2013)... (PRWEB) June 17, 2013 Nearly 26 ... as many as 79 million adults are estimated to ... to prevent type 2 diabetes through weight loss and ... can help bring your blood sugar level back within ... and factors, 101 Medical Weight Loss physicians can help ...
(Date:6/17/2013)... men with low-risk, localized prostate cancers can safely ... undergoing immediate treatment and have better quality of ... a study by researchers at Dana-Farber Cancer Institute ... June 18 issue of the Annals of ... models showed that "observation is a reasonable and, ...
(Date:6/17/2013)... Vegas Hotel Escapes, the top Las Vegas ... Berlin at the Lavo. Those traveling to Las Vegas to ... affordable rates we are offering. , VegasHotelEscapes is pleased ... hotels in Las Vegas on the strip , such as ... VegasHotelEscapes.com is pleased to offer the absolute lowest prices possible ...
(Date:6/17/2013)... Harvard Stem Cell Institute (HSCI) researchers have identified in ... to regulate embryonic stem cell self-renewal, beginning a creative ... , The gene, SALL4, gives stem cells their ability ... mature cells. Typically, cells only express SALL4 during embryonic ... cases of acute myeloid leukemia and 10 to 30 ...
Breaking Medicine News(10 mins):Health News:The Facebook effect: Social media dramatically boosts organ donor registration 2Health News:The Facebook effect: Social media dramatically boosts organ donor registration 3Health News:Best Diet Plans for Diabetics; Tips from 101 Medical Weight Loss 2Health News:Best Diet Plans for Diabetics; Tips from 101 Medical Weight Loss 3Health News:Best Diet Plans for Diabetics; Tips from 101 Medical Weight Loss 4Health News:Observation is safe, cost-saving in low-risk prostate cancer 2Health News:Observation is safe, cost-saving in low-risk prostate cancer 3Health News:A new target for cancer drug development 2
... the Sally Clark case could lead to a halving in the ... legacy emerging from tragedy, says a feature in this weeks BMJ. ... of her two infant sons. She was imprisoned but won her ... of the case, says Jonathan Gornall, have been devastating for her ...
... investigated and debated for its impact on health conditions ... effects on the body, coffee or its components ... levels on a short-term basis or cross-sectionally. These and ... risk of gout, the most prevalent inflammatory arthritis in ...
... over the past 40 years in England, owing to changes ... finds research published ahead of print in the British Journal ... geographical variation in rates suggest that the NHS is now ... training, say the authors. ,The research team analysed ...
... BMA says it is extremely concerned at the growing interest of ... the belief that these can be non lethal. ,The ... Science, concludes that it is impossible to deliver the right drug ... that is both effective and does not cause significant deaths. The ...
... an average of four to seven glasses of red wine ... with prostate cancer as those who do not drink ... Health Watch. In addition, red wine appears particularly protective against ... information about many factors that might influence the risk of ...
... A decade-long study by neurologists at the University of ... found a link between the increasingly popular weight-loss ... conditions. ,Katalin Juhasz Pocsine, M.D., associate ... author of the study. The study concludes that patients ...
Cached Medicine News:Health News:New Reforms Could Cut the Number of Unexplained Infant Deaths 2Health News:Four Cups of Coffee a Day may Cut Down the Risk of Gout 2Health News:Four Cups of Coffee a Day may Cut Down the Risk of Gout 3Health News:NHS Oversupplied With Cataract Surgery, Say Doctors 2Health News:Using Drugs as Weapons can Never Be 'non Lethal', Say Doctors 2Health News:Link Between Gastric Bypass Surgery and Neurological Conditions 2
Micro-hematocrit tubes available in multiple sizes and additives for a wide range of capillary blood collection....
... VH IVUS technology uses advanced spectral ... of ultrasound images and provide detailed ... patient's atherosclerotic plaques. The colorized VH ... fibrous, fibro-fatty, dense calcium, and necrotic ...
... Innova 2100IQ: See the finest vessels from ... devices. Its all enabled by the Revolution ... deliver excellent image quality and dose efficiency. ... installed worldwide, more physicians rely on these ...
... as Antidiurectic Hormone (ADH), is synthesized in ... flow to the posterior pituitary for storage ... by changes in blood osmolality and also ... blood volume or arterial pressure. Non-osmotic stimuli ...
Medicine Products: